Abstract
BackgroundThalidomide, a potent member of the immunomodulatory drug family, induces both direct myeloma cell death and indirect antimyeloma response through its impact on the microenvironment. The drug is approved in...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
